High dose iv steroids side effects

2. Fosfomycin (PO)
Bactericidal agent that is excreted into the urine and inhibits cell wall synthesis by interfering with peptidoglycan synthesis.
Spectrum: Broad spectrum vs Gram positive including MRSA, VRE; Gram negative including Pseudomonas and some ESBL’s . 
Used for: Uncomplicated urinary tract infections in women, especially in those with history of resistant bugs.  Given as a one-time mega-dose of 3 g (excreted into urine and achieves high levels there for several days.   Sometimes used for complicated UTI’s in males with resistant pathogens (3 g PO q3 days x several doses), although this is an off-label use.

ZYTIGA ® is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. Avoid co-administration with CYP2D6 substrates with a narrow therapeutic index. If alternative treatments cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate drug. In a CYP2C8 drug interaction trial in healthy subjects, the AUC of pioglitazone, a CYP2C8 substrate, was increased by 46% when administered with a single dose of ZYTIGA®. Patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with ZYTIGA ® .

I didn’t reach bowel tolerance until a little over 90gm per day (apx. 10+ gm every two hours). Doesn’t surprise me a lot. Before I got breast cancer, I rarely ate fruits or vegetables, except what came in those highly processed Lean Cuisine frozen meals. I subsisted largely off of grains (cereals) and too many sweets. I wish I had known better. Getting cancer was a true wake-up call. Chris, I am SO thankful for this site. I have RADICALLY changed EVERYTHING about the way I eat, and I truly have hope that the cancer will eventually clear out of my body. Thank you again!!!

A teratology study in pregnant cynomolgus monkeys given imipenem-cilastatin sodium at doses of 40 mg/kg/day (bolus intravenous injection) or 160 mg/kg/day (subcutaneous injection) resulted in maternal toxicity including emesis , inappetence, body weight loss, diarrhea, abortion , and death in some cases. In contrast , no significant toxicity was observed when non-pregnant cynomolgus monkeys were given doses of imipenem-cilastatin sodium up to 180 mg/kg/day (subcutaneous injection). W hen doses of imipenemcilastatin sodium (approximately 100 mg/kg/day or approximately times2 the maximum recommended daily human dose of the intravenous formulation) were administered to pregnant cynomolgus monkeys at an intravenous infusion rate which mimics human clinical use, there was minimal maternal intolerance (occasional emesis), no maternal deaths, no evidence of teratogenicity, but an increase in embryonic loss relative to control groups.

Cardiovascular risk factors include the alteration or diminishing of her glucose tolerance and hyperinsulinism (become resistant to insulin), a change in lipoproteins (carry cholesterol in blood) fraction which can cause cardiovascular disease and atherosclerosis (deposition of fatty substances onto inner walls of arteries causing blockage), increased triglyceride levels, hypertension (abnormally high blood pressure), changes in her myocardium (middle muscular layer of heart wall), and increased concentration levels of several different clotting factors.  Cardiomyopathy (a typically chronic disorder of heart muscle that may involve hypertrophy and obstructive damage to the heart), myocardial infarction (localized death of the myocardium tissue usually leading to heart failure), heart attack, stroke, and cerebro-vascular accidents have all been causes in deaths where AAS abuse was implicated.  Of course the liver, the body’s primary filtration system will come under attack as it has to accommodate the increased toxicity.  Among the liver problems promoted are holestatic jaundice (failure of bile flow that causes yellowish pigmentation of skin, tissues, and body fluids), peliosis hepatis (blood-filled cysts develop on liver), hepatocellular hyperplasia (unusual increase of an epithelial parenchymatous cell called hepatocytes in the liver), and cancer.  Secondary filters such as the kidneys and gallbladder also become more susceptible to disease.

Prednisone is a drug that belongs to the corticosteroid drug class, and is an anti-inflammatory and immune system suppressant. It's used to treat a variety of diseases and conditions, for example: inflammatory bowel disease (Crohn's disease and ulcerative colitis), lupus, asthma, cancers, and several types of arthritis.

Common side effects are weight gain, headache, fluid retention, and muscle weakness. Other effects and adverse events include glaucoma, cataracts, obesity, facial hair growth, moon face, and growth retardation in children. This medicine also causes psychiatric problems, for example: depression, insomnia, mood swings, personality changes, and psychotic behavior. Serious side effects include reactions to diabetes drugs, infections, and necrosis of the hips and joints.

Corticosteroids like prednisone, have many drug interactions; examples include: estrogens, phenytoin (Dilantin), diuretics, warfarin (Coumadin, Jantoven), and diabetes drugs. Prednisone is available as tablets of 1, , 10, 20, and 50 mg; extended release tablets of 1, 2, and 5mg; and oral solution of 5mg/5ml. It's use during the first trimester of pregnancy may cause cleft palate. This medicine is secreted in breast milk and can cause side effects in infants who are nursing. You should not stop taking prednisone abruptly because it can cause withdrawal symptoms and adrenal failure. Talk with your doctor, pharmacist, or other medical professional if you have questions about beta-blockers. Talk with your doctor, pharmacist, or other medical professional if you have questions about prednisone.

If you notice other effects not listed above, contact your doctor or pharmacist. In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

High dose iv steroids side effects

high dose iv steroids side effects

A teratology study in pregnant cynomolgus monkeys given imipenem-cilastatin sodium at doses of 40 mg/kg/day (bolus intravenous injection) or 160 mg/kg/day (subcutaneous injection) resulted in maternal toxicity including emesis , inappetence, body weight loss, diarrhea, abortion , and death in some cases. In contrast , no significant toxicity was observed when non-pregnant cynomolgus monkeys were given doses of imipenem-cilastatin sodium up to 180 mg/kg/day (subcutaneous injection). W hen doses of imipenemcilastatin sodium (approximately 100 mg/kg/day or approximately times2 the maximum recommended daily human dose of the intravenous formulation) were administered to pregnant cynomolgus monkeys at an intravenous infusion rate which mimics human clinical use, there was minimal maternal intolerance (occasional emesis), no maternal deaths, no evidence of teratogenicity, but an increase in embryonic loss relative to control groups.

Media:

high dose iv steroids side effectshigh dose iv steroids side effectshigh dose iv steroids side effectshigh dose iv steroids side effectshigh dose iv steroids side effects